These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 5329616)

  • 21. [The treatment of essential hyperlipidemia with clofibrate].
    Reuter W; Seifert A
    Z Gesamte Inn Med; 1969 Jan; 24(1):Suppl:184-7. PubMed ID: 4918619
    [No Abstract]   [Full Text] [Related]  

  • 22. The coronary drug project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. The coronary drug project research group.
    JAMA; 1972 May; 220(7):996-1008. PubMed ID: 4337170
    [No Abstract]   [Full Text] [Related]  

  • 23. Lipid lowering agents.
    Br Med J; 1972 Jun; 2(5814):642-3. PubMed ID: 5031693
    [No Abstract]   [Full Text] [Related]  

  • 24. Essential hyperlipemia with xanthomatosis: effects of cholestyramine and clofibrate.
    Roe DA
    Arch Dermatol; 1968 Apr; 97(4):436-45. PubMed ID: 5643239
    [No Abstract]   [Full Text] [Related]  

  • 25. Diet and drugs in the treatment of hyperlipidemias.
    Med Lett Drugs Ther; 1970 May; 12(10):42-4. PubMed ID: 5514225
    [No Abstract]   [Full Text] [Related]  

  • 26. Drug therapy of hyperlipoproteinemia.
    Levy RI
    JAMA; 1976 May; 235(21):2334-6. PubMed ID: 946632
    [No Abstract]   [Full Text] [Related]  

  • 27. The coronary drug project--findings with regard to estrogen, dextrothyroxine, clofibrate and niacin.
    Stamler J
    Adv Exp Med Biol; 1977; 82():52-75. PubMed ID: 335823
    [No Abstract]   [Full Text] [Related]  

  • 28. [Arteriosclerosis--nicotinic acid therapy. 10. Combination therapy in hyperlipemia].
    Hansen PF
    Lakartidningen; 1971 Apr; 68(15):1769-72. PubMed ID: 5577252
    [No Abstract]   [Full Text] [Related]  

  • 29. Hypolipidemic agents--newly approved.
    Duncan GG
    Pa Med; 1967 Aug; 70(8):75-6. PubMed ID: 6073724
    [No Abstract]   [Full Text] [Related]  

  • 30. [The therapeutic value of "Essential" phospholipids].
    Pristautz H
    MMW Munch Med Wochenschr; 1975 Apr; 117(14):583-6. PubMed ID: 806790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of essential hyperlipidaemia.
    Fredrickson DS; Levy RI
    Lancet; 1970 Jan; 1(7639):191-2. PubMed ID: 4189261
    [No Abstract]   [Full Text] [Related]  

  • 32. Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy.
    Oki JC
    Pharmacotherapy; 1995; 15(3):317-37. PubMed ID: 7667166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of halofenate on serum lipids.
    Aronow WS; Harding PR; Khursheed M; Vangrow JS; Papageorge's NP; Mays J
    Clin Pharmacol Ther; 1973; 14(3):358-65. PubMed ID: 4572798
    [No Abstract]   [Full Text] [Related]  

  • 34. Effects of dextrothyroxine on serum lipoprotein and cholesterol levels.
    Searcy RL; Hungerford DA; Low EM
    Curr Ther Res Clin Exp; 1968 Apr; 10(4):177-86. PubMed ID: 4967872
    [No Abstract]   [Full Text] [Related]  

  • 35. [Clinical testing of a combination of clofibrate and beta-pyridylcarbinol in an unusual dosis relation].
    Mann S; Maisenbacher HJ
    Z Allgemeinmed; 1975 Aug; 51(24):1066-71. PubMed ID: 1101545
    [No Abstract]   [Full Text] [Related]  

  • 36. Aggressive medical therapy for the prevention and treatment of coronary artery disease.
    Malloy MJ; Kane JP
    Dis Mon; 1998 Jan; 44(1):1-40. PubMed ID: 9457050
    [No Abstract]   [Full Text] [Related]  

  • 37. The effect on serum tocopherol levels of drug-induced decrease in serum lipids.
    Weiss P; Bianchine JR
    Am J Med Sci; 1969 Oct; 258(4):275-81. PubMed ID: 5823464
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical and metabolic effects of pentaerythritol tetranicotinate in combination with cholesolvin or clofibrate.
    Olsson AG; Orö L; Rössner S
    Atherosclerosis; 1974; 19(3):407-15. PubMed ID: 4364073
    [No Abstract]   [Full Text] [Related]  

  • 39. Clinical trial of methyl clofenapate (a derivative of clofibrate) in patients with essential hyperlipidaemias--with special reference to type II (primary) hyperlipidaemia.
    Craig GM; Walton KW
    Atherosclerosis; 1972; 15(2):189-98. PubMed ID: 4579956
    [No Abstract]   [Full Text] [Related]  

  • 40. [Medical treatment of hyperlipemia. Indications and modern preparations].
    Frey H
    Tidsskr Nor Laegeforen; 1968 Jan; 88(2):6-8. PubMed ID: 5663311
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.